CerraCap Ventures announced on February 10 an investment in Predicta Med. Terms of the deal were not disclosed.
Headquartered in Tel Aviv, Israel, Predicta Med is an AI-based digital health company in the field of predictive analytics. The company helps medical clinics and institutions identify immune-related diseases.
CerraCap Ventures is a Costa Mesa, California-based venture capital firm dedicated to early-stage technology investments in enterprise B2B solutions, including cybersecurity and health care.
According to data captured in the LevinPro HC database, this acquisition represents the 16th Laboratories, MRI and Dialysis transaction of 2023 and the ninth in the diagnostics subsector. There were 22 Laboratories, MRI and Dialysis, including 18 diagnostics acquisitions, announced between January 1, 2022, and February 10, 2022.
